# Pizarra — PT-pseudo_033f1a8e1503 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_033f1a8e1503
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.199 ng/mL²
  - PSA velocity: 1.83 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 29.71 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84285355 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.

Vitals: weight 82 kg, height 184 cm, BMI 24.2, BP 113/77 mmHg, HR 77 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2022).

Chief complaint: Routine monitoring after mpMRI completion and detection of an upward PSA trajectory.

History: A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions.

Physical examination: DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Audiology — hearing test.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.85 +/- 0.07   (95% CI 0.71-0.99)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.07  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.62 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report detail the lesion size, zone, and comparison against earlier studies?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the patient's prior management context, including prior grade and surveillance pathway?

This case hinges on the detailed findings from the mpMRI, the PSA trajectory, and the prior management plan to determine the necessity of a biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (5.9 ng/mL), PI-RADS (5), PSA density (0.199 ng/mL²), PSA velocity (1.83 ng/mL/yr), and csPCa probability (0.84285355). It cannot weigh the qualitative information from the mpMRI prose, such as lesion size, zone, or comparison to prior studies, which are crucial for assessing the certainty of the PI-RADS 5 score.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (0.85), but the guideline criterion is based only on PI-RADS $\ge 3$, which is met. However, the guideline notes that a PI-RADS 5 lesion has an 83% detection rate for csPCa, suggesting the high probability might be inflated by the high PI-RADS score alone, without accounting for the specific clinical context or the need for perilesional sampling. Furthermore, the prior does not account for the fact that the patient is biopsy-naive, which is a factor mentioned in the guideline context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the mpMRI report detail the lesion size, zone, and comparison against earlier studies?
psa_trend - what is the serial PSA trend and velocity beyond the headline value?
previous_notes - what is the patient's prior management context, including prior grade and surveillance pathway?
laboratory panel - what are the full laboratory results?
GUIDELINE ANCHOR
The guideline states that a PI-RADS $\ge 3$ triggers biopsy, and that MRI-directed biopsy is the standard of care.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the left peripheral zone, measuring 12 x 9 x 10 mm. No comparison with a previous MRI was explicitly detailed in the report prose.
get_psa_trend
PSA trend: Apr 2022: 4.2 ng/mL; Sep 2023: 3.4 ng/mL; Jan 2025: 5.9 ng/mL. Velocity is upward.
get_previous_notes
Previous notes: Last PSA rise to 4.1 ng/mL in Sep 2023. mpMRI was ordered based on this trend. Patient was on Tamsulosin for LUTS. No prior biopsy grade was recorded.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly request it, and no information from the retrieved documents raised a specific question requiring it.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left peripheral zone, 12 x 9 x 10 mm.
- PSA trend: Upward trajectory from 3.4 ng/mL (Sep 2023) to 5.9 ng/mL (Jan 2025).
- Previous notes: mpMRI was ordered based on a prior PSA rise to 4.1 ng/mL.

AGAINST sampling this patient now:
- MRI report: No comparison with a previous MRI was explicitly detailed in the report prose.
- Previous notes: No prior biopsy grade was recorded.

WHERE THIS LEANS
The evidence strongly supports the need for further investigation due to the PI-RADS 5 score and the rising PSA velocity. This confirms the statistical prior and the guideline criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 5 finding from the MRI and the upward PSA trend, strongly supports the guideline criterion for biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all sources. The PI-RADS 5 score from the mpMRI was decisive, aligning with the guideline criterion for biopsy when PI-RADS is 3 or higher. This was further supported by the upward PSA trend from 3.4 ng/mL to 5.9 ng/mL, which was retrieved evidence. The statistical prior also suggested biopsy, and the retrieved findings confirmed the clinical protocol.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
